Hasnain Arshad is a Neurology physician. OpenAlex indexes 10 publications with 202 citations (h-index 3).
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
232 W 25th St
Erie, PA 165440002
Telephone
814-452-7575Provider last certified this registry record 3 Sept 2025.
Industry payments
7 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- ARGENX US, INC.Program year20232 payments
- Alnylam Pharmaceuticals Inc.Program year20221 payment
- ABBVIE INC.Program year20221 payment
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
84.3%Gabapentinoids34.1%Pregabalin63%Gabapentin33%Lyrica4%Part D<11 patientsCholinesterase Inhibitor14.6%Pyridostigmine Bromide89%Donepezil Hcl11%Part D<11 patients+ 11 more classes in this area
Musculoskeletal
9.7%gamma-Aminobutyric Acid-ergic Agonist5%Baclofen100%Part D≥13 patientsMuscle Relaxant2.7%Cyclobenzaprine Hcl100%Part D<11 patients+ 1 more class in this area
Metabolism & gastrointestinal
6.1%Corticosteroid6.1%Prednisone100%Part D≥17 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Case: A Case of pembrolizumab induced myocarditis and complete heart block
Journal of Community Hospital Internal Medicine Perspectives
2024 - Long-term Anticoagulation with Apixaban in Patients with Cerebral Venous Thrombosis
Clinical and Applied Thrombosis/Hemostasis
2023
Similar KOLs
Other experts from the same institution or the same specialty.
Atte Meretoja
University of Helsinki
Bruce Miller, MD
University of California, San Francisco (UCSF)
Dennis Selkoe, MD
Brigham and Women's Hospital
Ettore Beghi
Mario Negri Institute for Pharmacological Research
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”